Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.58 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26230945 | 0.88 | P2RY1 (0.47) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL3457849 | 0.88 | EGFR (0.54) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL9702446 | 0.86 | CYP1A2 (0.51) | ADORA2AADORA1TMIGD3PDE4APDE4B | |
| SCHEMBL7263226 | 0.86 | ADORA2A (0.52) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL7262510 | 0.86 | ADORA2A (0.52) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL7262512 | 0.86 | ADORA2A (0.52) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL26230942 | 0.86 | P2RY1 (0.47) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL31087988 | 0.85 | NPC1 (0.49) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL8646398 | 0.85 | FLT4 (0.50) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL2758372 | 0.83 | CDK1 (0.56) | ADORA2AADORA1ADORA3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210087220-A1 | PRODUCTION OF HIGHLY FAT-SOLUBLE PHOSPHORAMIDITE | KNC LABORATORIES CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-10947533-B2 | Processes for preparing phosphorodiamidate morpholino oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200407392-A1 | LNA-DICARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10875880-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-02-06 | — | — | US | disclosed |
| WO-2018057430-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | NOP2, PCBP1, RNGTT | ADORA2A 4356/4885ADORA1 4299/4885TMIGD3 3966/4885 |
| US-20200407392-A1 | LNA-DICARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | POLR2H, POLRMT, SLC16A1 | ADORA2A 1310/4885ADORA1 528/4885TMIGD3 4695/4885 |
| US-20210087220-A1 | PRODUCTION OF HIGHLY FAT-SOLUBLE PHOSPHORAMIDITE | RNGTT, POLR2A, POLR2H | ADORA2A 360/4885ADORA1 204/4885TMIGD3 4874/4885 |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | PCBP1, RNGTT, PHAX | ADORA2A 4556/4885ADORA1 4549/4885TMIGD3 4175/4885 |
| US-10875880-B2 | Processes for preparing oligomers | NOP2, PCBP1, RNGTT | ADORA2A 4356/4885ADORA1 4299/4885TMIGD3 3966/4885 |
| US-11384105-B2 | Processes for preparing oligomers | NOP2, RNGTT, PCBP1 | ADORA2A 4483/4885ADORA1 4477/4885TMIGD3 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.